Table 2 Characteristics of mucormycosis and patients’ outcome
N (%) or Median (IQR) | All n = 26 | Survivors in ICU n = 6 | Non survivors in ICU n = 20 | P value |
|---|---|---|---|---|
Diagnosisa | 0.12 | |||
Proven | 14 (54) | 2 (33) | 12 (60) | |
Probable | 5 (19) | 3 (50) | 2 (10) | |
Possible with positive qPCR | 7 (27) | 1 (17) | 6 (30) | |
Involvement | ||||
Pulmonary | 16 (62) | 4 (67) | 12 (60) | 1.00 |
Rhino-cerebral | 10 (38) | 3 (50) | 7 (35) | 0.85 |
Digestive | 5 (19) | 0 | 5 (25) | 0.44 |
Skin | 2 (8) | 0 | 2 (10) | 1.00 |
Disseminated | 8 (31) | 1 (17) | 7 (35) | 0.73 |
Species | 0.45 | |||
Rhizopus/Mucor | 8 (31) | 3 (50) | 5 (25) | |
Lichteimia | 3 (12) | 0 | 3 (15) | |
Rhizomucor | 2 (8) | 0 | 2 (10) | |
Lichteimia/Rizomucor | 1 (4) | 0 | 1 (5) | |
Rhizopus | 1 (4) | 0 | 1 (5) | |
Mucor | 1 (4) | 0 | 1 (5) | |
Unknown | 10 (38) | 3 (50) | 7 (35) | |
Concomitant infection | ||||
Fungal | 8 (31) | 3 (50) | 5 (25) | 1.00 |
Bacterial | 8 (31) | 2 (33) | 6 (30) | 0.51 |
Viral | 4 (15) | 0 | 4 (20) | 0.59 |
Specific treatments | ||||
Antifungal therapy | ||||
- Curative L-AmB | 22 (85) | 6 (100) | 16 (80) | 0.59 |
- Initial dosage of curative L-AmB | 5.0 [5.0–10.0] | 10.0 [5.0–10.0] | 5.0 [5.0–5.8] | 0.86 |
- Maximal dosage of curative L-AmB | 10.0 [5.5–10.0] | 10.0 [8.1–10.0] | 10.0 [5.0–10.0] | 0.28 |
- Dual therapy | 12 (46) | 4 (67) | 8 (40) | 0.50 |
Curative surgery | 8 (31) | 2 (33) | 6 (30) | 1.00 |
Outcomes | ||||
Length of ICU stay (days) | 6.0 [2.3–10.8] | 4.0 [1.8–5.5] | 8.5 [2.8–17.5] | 0.18 |
Length of hospital stay (days) | 28.5 [21.0–41.3] | 25.0 [15.0–37.0] | 29.0 [22.0–44.5] | 0.64 |
End-of-life decision | 14 (54) | 3 (50) | 11 (90) | 1.00 |